Cartesian Therapeutics, Inc.
NASDAQ:RNACBiotechnology
-$0.41 today
- Market cap
- $192.17M
- Beta
- 0.78
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$5.65
Volume 0.17M
Average 0.26M
Balance Sheet
Inspect the capital base behind the business.
Assets
$296.41M
FY 2025 · Annual
-31.9% YoYLiabilities
$422.65M
FY 2025 · Annual
-4.3% YoYEquity
-$126.24M
FY 2025 · Annual
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114.06M | 106.44M | 76.91M | 212.61M | 125.14M |
| Short-term Investments | 14M | 28.16M | 0 | 0 | 0 |
| Net Receivables | 9.91M | 9.86M | 8.85M | 872K | 1.12M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 3.68M | 4.97M | 3.14M | 3.02M |
| Total Current Assets | 144.44M | 148.14M | 90.73M | 216.63M | 129.28M |
| Property, Plant & Equipment (Net) | 11.97M | 14.41M | 12.18M | 15.45M | 17.79M |
| Goodwill | 0 | 0 | 48.16M | 48.16M | 48.16M |
| Intangible Assets | 0 | 0 | 150.6M | 150.6M | 0 |
| Long-term Investments | 2M | 2M | 2M | 2M | 1.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.47M | 1.34M | 1.38M | 2.19M | 99.45M |
| Total Non-current Assets | 15.44M | 17.75M | 214.32M | 218.4M | 167.14M |
| Total Assets | 159.88M | 165.89M | 305.05M | 435.02M | 296.41M |
| Account Payables | 224K | 316K | 3.15M | 288K | 1.29M |
| Short-term Debt | 5.96M | 8.48M | 0 | 0 | 4.15M |
| Tax Payables | 601K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 53.88M | 593K | 2.31M | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 56.19M | 7.76M | 5.51M |
| Total Current Liabilities | 72.25M | 25.08M | 68.21M | 22.98M | 14.94M |
| Long-term Debt | 19.67M | 17.79M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 322.08M | 16.14M | 6.95M |
| Deferred Revenue (Non-current) | 11.42M | 0 | 3.54M | 0 | 0 |
| Other Non-current Liabilities | 25.42M | 19.14M | 342.62M | 391.58M | 392.24M |
| Total Non-current Liabilities | 65.11M | 46.98M | 677.03M | 418.85M | 407.71M |
| Total Liabilities | 137.36M | 72.06M | 745.23M | 441.83M | 422.65M |
| Common Stock | 12K | 15K | 16K | 3K | 3K |
| Retained Earnings | (430.32M) | (394.94M) | (614.65M) | (692.07M) | (822.37M) |
| Accumulated OCI | (4.57M) | (4.56M) | (4.6M) | (4.62M) | (4.58M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 22.52M | 93.83M | (440.18M) | (6.8M) | (126.24M) |
| Total Debt | 35.28M | 37.93M | 10.96M | 13.98M | 12.68M |
| Net Debt | (78.78M) | (68.51M) | (65.96M) | (198.63M) | (112.46M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $118.6M |
| Receivables | $261.0K |
| Other Current | $3.1M |
| Total Current Assets | $122.0M |
| PP&E (Net) | $17.0M |
| Goodwill | $48.2M |
| Intangible Assets | $93.9M |
| Long-term Investments | $1.7M |
| Other Non-current | $5.6M |
| Total Non-current Assets | $166.4M |
| Total Assets | $288.4M |
Analysis
Selected assets total $288.4M for Latest. The largest visible component is Cash & Equivalents at $118.6M, about 41.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Sep 29, 2026 | |
| SC 13G | SC 13G filing | Aug 13, 2026 |
How much cash does RNAC have?
Cartesian Therapeutics, Inc. (RNAC) reported $125.14M in cash and equivalents in fiscal 2025.
How much debt does RNAC carry?
Cartesian Therapeutics, Inc. (RNAC) reported $12.68M of total debt, with net debt of -$112.46M.
Continue the stock analysis
Jump to another research area for this company.